interactions:
- request:
    body: retmax=1000&db=pubmed&retmode=xml&api_key=<omitted>&id=20301382
    headers:
      Accept:
      - application/json
      Accept-Encoding:
      - gzip, deflate
      Connection:
      - keep-alive
      Content-Length:
      - '90'
      Content-Type:
      - application/x-www-form-urlencoded
      User-Agent:
      - hawc
    method: POST
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi
  response:
    body:
      string: '<?xml version="1.0" ?>

        <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January
        2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">

        <PubmedArticleSet>

        <PubmedBookArticle><BookDocument><PMID Version="1">20301382</PMID><ArticleIdList><ArticleId
        IdType="bookaccession">NBK1203</ArticleId></ArticleIdList><Book><Publisher><PublisherName>University
        of Washington, Seattle</PublisherName><PublisherLocation>Seattle (WA)</PublisherLocation></Publisher><BookTitle
        book="gene">GeneReviews<sup>&#xae;</sup></BookTitle><PubDate><Year>1993</Year></PubDate><BeginningDate><Year>1993</Year></BeginningDate><EndingDate><Year>2024</Year></EndingDate><AuthorList
        Type="editors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Margaret
        P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Jerry</ForeName><Initials>J</Initials></Author><Author
        ValidYN="Y"><LastName>Mirzaa</LastName><ForeName>Ghayda M</ForeName><Initials>GM</Initials></Author><Author
        ValidYN="Y"><LastName>Pagon</LastName><ForeName>Roberta A</ForeName><Initials>RA</Initials></Author><Author
        ValidYN="Y"><LastName>Wallace</LastName><ForeName>Stephanie E</ForeName><Initials>SE</Initials></Author><Author
        ValidYN="Y"><LastName>Bean</LastName><ForeName>Lora JH</ForeName><Initials>LJH</Initials></Author><Author
        ValidYN="Y"><LastName>Gripp</LastName><ForeName>Karen W</ForeName><Initials>KW</Initials></Author><Author
        ValidYN="Y"><LastName>Amemiya</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author></AuthorList><Medium>Internet</Medium></Book><ArticleTitle
        book="gene" part="kss">Single Large-Scale Mitochondrial DNA Deletion Syndromes</ArticleTitle><Language>eng</Language><AuthorList
        Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mitochondrial
        Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics,
        Children''s Hospital of Philadelphia, University of Pennsylvania Perelman
        School of Medicine, Philadelphia, Pennsylvania</Affiliation></AffiliationInfo></Author><Author
        ValidYN="Y"><LastName>Falk</LastName><ForeName>Marni J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Mitochondrial
        Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics,
        Children''s Hospital of Philadelphia, University of Pennsylvania Perelman
        School of Medicine, Philadelphia, Pennsylvania</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType
        UI="D016454">Review</PublicationType><Abstract><AbstractText Label="CLINICAL
        CHARACTERISTICS">Single large-scale mitochondrial DNA deletion syndromes (SLSMDSs)
        comprise overlapping clinical phenotypes including Kearns-Sayre syndrome (KSS),
        KSS spectrum, Pearson syndrome (PS), chronic progressive external ophthalmoplegia
        (CPEO), and CPEO-plus. <i>KSS</i> is a progressive multisystem disorder with
        onset before age 20 years characterized by pigmentary retinopathy, CPEO, and
        cardiac conduction abnormality. Additional features can include cerebellar
        ataxia, tremor, intellectual disability or cognitive decline, dementia, sensorineural
        hearing loss, oropharyngeal and esophageal dysfunction, exercise intolerance,
        muscle weakness, and endocrinopathies. Brain imaging typically shows bilateral
        lesions in the globus pallidus and white matter. <i>KSS spectrum</i> includes
        individuals with KSS in addition to individuals with ptosis and/or ophthalmoparesis
        and at least one of the following: retinopathy, ataxia, cardiac conduction
        defects, hearing loss, growth deficiency, cognitive impairment, tremor, or
        cardiomyopathy. Compared to CPEO-plus, individuals with KSS spectrum have
        more severe muscle involvement (e.g., weakness, atrophy) and overall have
        a worse prognosis. <i>PS</i> is characterized by pancytopenia (typically transfusion-dependent
        sideroblastic anemia with variable cell line involvement), exocrine pancreatic
        dysfunction, poor weight gain, and lactic acidosis. PS manifestations also
        include renal tubular acidosis, short stature, and elevated liver enzymes.
        PS may be fatal in infancy due to neutropenia-related infection or refractory
        metabolic acidosis. <i>CPEO</i> is characterized by ptosis, ophthalmoplegia,
        oropharyngeal weakness, variable proximal limb weakness, and/or exercise intolerance.
        <i>CPEO-plus</i> includes CPEO with additional multisystemic involvement including
        neuropathy, diabetes mellitus, migraines, hypothyroidism, neuropsychiatric
        manifestations, and optic neuropathy. Rarely, an SLSMDS can manifest as <i>Leigh
        syndrome</i>, which is characterized as developmental delays, neurodevelopmental
        regression, lactic acidosis, and bilateral symmetric basal ganglia, brain
        stem, and/or midbrain lesions on MRI.</AbstractText><AbstractText Label="DIAGNOSIS/TESTING">The
        diagnosis of an SLSMDS is established in a proband with characteristic clinical
        features by identification of a mitochondrial DNA (mtDNA) deletion ranging
        in size from 1.1 to 10 kb on molecular genetic testing. SLSMDSs can be identified
        in DNA from blood, buccal cells, and urine in affected children; analysis
        of skeletal muscle tissue may be required to detect an SLSMDS in an affected
        adult.</AbstractText><AbstractText Label="MANAGEMENT"><i>Targeted therapy:</i>
        Folinic acid supplementation in individuals with KSS with low 5-methyltetrahydrofolate
        in CSF or white matter abnormalities on brain MRI. <i>Supportive care:</i>
        Consider mitochondrial supplement therapies such as coenzyme Q<sub>10</sub>
        and antioxidants; optimize nutrition and exercise regimen to prevent acute
        decompensation; physical and occupational therapy for myopathy and/or ataxia;
        standard treatment with anti-seizure medication; hearing aids or cochlear
        implants for sensorineural hearing loss; developmental and educational support;
        feeding therapy; consider gastrostomy tube placement if poor weight gain,
        choking, or aspiration risk is present; dilation of the upper esophageal sphincter
        to alleviate cricopharyngeal achalasia; prophylactic placement of cardiac
        pacemaker in individuals with cardiac conduction block, with consideration
        of an implantable cardioverter defibrillator; hormone replacement therapy
        per endocrinologist; electrolyte monitoring and replacement for renal tubular
        acidosis; eyelid slings and/or ptosis repair for severe ptosis; eye ointment
        for dry eyes; eyeglass prisms for diplopia; transfusion therapy for individuals
        with PS with sideroblastic anemia; replacement of pancreatic enzymes for exocrine
        pancreatic insufficiency; ventilatory support for respiratory abnormalities
        that may occur in individuals with Leigh syndrome; standard treatment of anxiety
        and/or depression; social work support and care coordination as needed. <i>Surveillance:</i>
        Annual neurology assessment for ataxia, neuropathy, seizures, and myopathy;
        annual audiology evaluation; annual assessment of developmental progress,
        educational needs, and cognitive issues; annual evaluation by a neuro-ophthalmologist
        and/or retinal specialist and oculoplastics; measurement of growth parameters
        and evaluation of nutritional status and safety of oral intake at each visit;
        annual assessment of mobility and self-help skills with physical medicine,
        occupational therapy, and/or physical therapy; EKG and echocardiogram every
        six to 12 months; annual assessment with an endocrinologist; BUN and creatinine,
        with consideration of cystatin C in those with low muscle mass; complete blood
        count in those with PS to assess transfusion needs with additional labs per
        hematologist, and ferritin for those needing recurrent transfusions as needed;
        annual complete blood count in those with other SLSMDSs; fecal fat and fecal
        elastase as needed based on symptoms; monitor for evidence of aspiration and
        respiratory insufficiency at each visit; assess family needs at each visit.
        <i>Agents/circumstances to avoid:</i> Volatile anesthetic hypersensitivity
        may occur. Avoid prolonged treatment with propofol (&gt;30-60 minutes). Medications
        should be reviewed with a physician familiar with mitochondrial disorders
        including a thorough individualized assessment of risk vs benefit as several
        medications may be toxic to mitochondria.</AbstractText><AbstractText Label="GENETIC
        COUNSELING">SLSMDSs are almost never inherited, suggesting that these disorders
        are typically caused by a <i>de novo</i> single large-scale mitochondrial
        DNA deletion (SLSMD) that occurs in the mother''s oocytes during germline
        development or in the embryo during embryogenesis. If the mother is clinically
        unaffected and the proband represents a simplex case (i.e., a single affected
        family member), the empiric risk to the sibs of a proband is very low (at
        or below 1%). If the mother is affected, the recurrence risk to sibs is estimated
        to be approximately 4% (one in 24 births). Maternal transmission to more than
        one child has not been reported to date. Prenatal testing for a pregnancy
        at increased risk and preimplantation genetic testing are scientifically possible
        but technically prohibitive as next-generation sequencing methodology does
        not accurately quantify heteroplasmy level of an SLSMD and droplet digital
        quantitative PCR cannot reliably detect less than 10% heteroplasmy levels
        of an SLSMD. Further, prenatal testing is not clinically available due to
        the inability to accurately interpret the clinical prognosis based on prenatal
        diagnostic results of an SLSMD.</AbstractText><CopyrightInformation>Copyright
        &#xa9; 1993-2024, University of Washington, Seattle. GeneReviews is a registered
        trademark of the University of Washington, Seattle. All rights reserved.</CopyrightInformation></Abstract><Sections><Section><SectionTitle
        book="gene" part="kss" sec="kss.Summary">Summary</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.GeneReview_Scope"><i>GeneReview</i> Scope</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Diagnosis">Diagnosis</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Clinical_Characteristics">Clinical Characteristics</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Genetically_Related_Disorders">Genetically
        Related Disorders</SectionTitle></Section><Section><SectionTitle book="gene"
        part="kss" sec="kss.Differential_Diagnosis">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Management">Management</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Genetic_Counseling">Genetic Counseling</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Resources">Resources</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Molecular_Genetics">Molecular Genetics</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.Chapter_Notes">Chapter Notes</SectionTitle></Section><Section><SectionTitle
        book="gene" part="kss" sec="kss.References">References</SectionTitle></Section></Sections><KeywordList
        Owner="NLM"><Keyword MajorTopicYN="N">mtDNA Deletion Syndromes</Keyword><Keyword
        MajorTopicYN="N">SLSMDS</Keyword><Keyword MajorTopicYN="N">mtDNA Deletion
        Syndromes</Keyword><Keyword MajorTopicYN="N">SLSMDS</Keyword><Keyword MajorTopicYN="N">Pearson
        Syndrome</Keyword><Keyword MajorTopicYN="N">Kearns-Sayre Syndrome (KSS)</Keyword><Keyword
        MajorTopicYN="N">Chronic Progressive External Ophthalmoplegia (CPEO)</Keyword><Keyword
        MajorTopicYN="N">Leigh Syndrome (mtDNA deletion)</Keyword><Keyword MajorTopicYN="N">CPEO-Plus</Keyword><Keyword
        MajorTopicYN="N">Kearns-Sayre Syndrome Spectrum</Keyword><Keyword MajorTopicYN="N">Single
        Large-Scale Mitochondrial DNA Deletion Syndromes</Keyword></KeywordList><ContributionDate><Year>2003</Year><Month>12</Month><Day>17</Day></ContributionDate><DateRevised><Year>2023</Year><Month>9</Month><Day>28</Day></DateRevised><ItemList
        ListType="Synonyms"><Item>mtDNA Deletion Syndromes</Item><Item>SLSMDS</Item></ItemList><ReferenceList><Reference><Citation>Al-Gadi
        IS, Haas RH, Falk MJ, Goldstein A, McCormack SE. Endocrine disorders in primary
        mitochondrial disease. J Endocr Soc. 2018;2:361-73.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC5865537</ArticleId><ArticleId IdType="pubmed">29594260</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter
        BP. Pearson syndrome in a Diamond-Blackfan anemia cohort. Blood. 2014;124:312-3.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC4102705</ArticleId><ArticleId IdType="pubmed">25035146</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcelos
        I, Shadiack E, Ganetzky RD, Falk MJ. Mitochondrial medicine therapies: rationale,
        evidence, and dosing guidelines. Curr Opin Pediatr. 2020;32:707-18.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC7774245</ArticleId><ArticleId IdType="pubmed">33105273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard
        AM, Vyskocil AA, Mahieu P, Lauwerys RR. Assessment of urinary retinol-binding
        protein as an index of proximal tubular injury. Clin Chem. 1987;33:775-9</Citation><ArticleIdList><ArticleId
        IdType="pubmed">3297418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosworth
        CM, Grandhi S, Gould MP, LaFramboise T. Detection and quantification of mitochondrial
        DNA deletions from next-generation sequence data. BMC Bioinformatics. 2017;18:407.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC5657046</ArticleId><ArticleId IdType="pubmed">29072135</ArticleId></ArticleIdList></Reference><Reference><Citation>Broomfield
        A, Sweeney MG, Woodward CE, Fratter C, Morris AM, Leonard JV, Abulhoul L,
        Grunewald S, Clayton PT, Hanna MG, Poulton J, Rahman S. Paediatric single
        mitochondrial DNA deletion disorders: an overlapping spectrum of disease.
        J Inherit Metab Dis. 2015;38:445-57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432108</ArticleId><ArticleId
        IdType="pubmed">25352051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinnery
        PF, DiMauro S, Shanske S, Schon EA, Zeviani M, Mariotti C, Carrara F, Lombes
        A, Laforet P, Ogier H, Jaksch M, Lochm&#xfc;ller H, Horvath R, Deschauer M,
        Thorburn DR, Bindoff LA, Poulton J, Taylor RW, Matthews JN, Turnbull DM. Risk
        of developing a mitochondrial DNA deletion disorder. Lancet. 2004;364:592-6.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">15313359</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa
        BL, Leon E, Calhoun A, Lowichik A, Pasquali M, Longo N. Biochemical abnormalities
        in Pearson syndrome. Am J Med Genet A. 2015;167A:621-8.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">25691415</ArticleId></ArticleIdList></Reference><Reference><Citation>Damas
        J, Carneiro J, Amorim A, Pereira F. MitoBreak: the mitochondrial DNA breakpoints
        database. Nucleic Acids Res. 2014;42:D1261-8.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC3965124</ArticleId><ArticleId IdType="pubmed">24170808</ArticleId></ArticleIdList></Reference><Reference><Citation>De
        Vries MC, Brown DA, Allen ME, Bindoff L, Gorman GS, Karaa A, Keshavan N, Lamperti
        C, McFarland R, Ng YS, O''Callaghan M, Pitceathly RDS, Rahman S, Russel FGM,
        Varhaug KN, Schirris TJJ, Mancuso M. Safety of drug use in patients with a
        primary mitochondrial disease: An international Delphi-based consensus. J
        Inherit Metab Dis. 2020;43:800-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383489</ArticleId><ArticleId
        IdType="pubmed">32030781</ArticleId></ArticleIdList></Reference><Reference><Citation>DiMauro
        S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348:2656-68</Citation><ArticleIdList><ArticleId
        IdType="pubmed">12826641</ArticleId></ArticleIdList></Reference><Reference><Citation>Eviatar
        L, Shanske S, Gauthier B, Abrams C, Maytal J, Slavin M, Valderrama E, DiMauro
        S. Kearns-Sayre syndrome presenting as renal tubular acidosis. Neurology.
        1990;40:1761-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">2234434</ArticleId></ArticleIdList></Reference><Reference><Citation>Farruggia
        P, Di Cataldo A, Pinto RM, Palmisani E, Macaluso A, Valvo LL, Cantarini ME,
        Tornesello A, Corti P, Fioredda F, Varotto S, Martire B, Moroni I, Puccio
        G, Russo G, Dufour C, Pillon M. Pearson syndrome: a retrospective cohort study
        from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia
        Pediatrica). JIMD Rep. 2016;26:37-43.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC4864774</ArticleId><ArticleId IdType="pubmed">26238250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganetzky
        RD, Falk MJ. 8-year retrospective analysis of intravenous arginine therapy
        for acute metabolic strokes in pediatric mitochondrial disease. Mol Genet
        Metab. 2018;123:301-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849405</ArticleId><ArticleId
        IdType="pubmed">29428506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman
        GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A,
        Thorburn DR, Zeviani M, Turnbull DM. Mitochondrial diseases. Nat Rev Dis Primers.
        2016;2:16080.</Citation><ArticleIdList><ArticleId IdType="pubmed">27775730</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady
        JP, Campbell G, Ratnaike T, Blakely EL, Falkous G, Nesbitt V, Schaefer AM,
        McNally RJ, Gorman GS, Taylor RW, Turnbull DM, McFarland R. Disease progression
        in patients with single, large-scale mitochondrial DNA deletions. Brain. 2014;137:323-34.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC3914470</ArticleId><ArticleId IdType="pubmed">24277717</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson
        MA, McCormick EM, Perera L, Longley MJ, Bai R, Kong J, Dulik M, Shen L, Goldstein
        AC, McCormack SE, Laskin BL, Leroy BP, Ortiz-Gonzalez XR, Ellington MG, Copeland
        WC, Falk MJ. Mitochondrial single-stranded DNA binding protein novel de novo
        SSBP1 mutation in a child with single large-scale mtDNA deletion (SLSMD) clinically
        manifesting as Pearson, Kearns-Sayre, and Leigh syndromes. PLoS One. 2019;14:e0221829.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC6719858</ArticleId><ArticleId IdType="pubmed">31479473</ArticleId></ArticleIdList></Reference><Reference><Citation>Herget-Rosenthal
        S, Poppen D, H&#xfc;sing J, Marggraf G, Pietruck F, Jakob HG, Philipp T, Kribben
        A. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute
        tubular necrosis. Clin Chem. 2004;50:552-8</Citation><ArticleIdList><ArticleId
        IdType="pubmed">14709451</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh
        VC, Krane EJ, Morgan PG. Mitochondrial disease and anesthesia. Journal of
        Inborn Errors of Metabolism &amp; Screening. 2017;5:1-5.</Citation></Reference><Reference><Citation>Kabunga
        P, Lau AK, Phan K, Puranik R, Liang C, Davis RL, Sue CM, Sy RW. Systematic
        review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial
        cytopathy. Int J Cardiol. 2015;181:303-10.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">25540845</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsanos
        KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathyroidism
        in Kearns-Sayre syndrome. Am J Nephrol. 2001;21:150-3.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">11359024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake
        NJ, Compton AG, Rahman S, Thorburn DR. Leigh syndrome: one disorder, more
        than 75 monogenic causes. Ann Neurol. 2016;79:190-203.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">26506407</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso
        M, Orsucci D, Angelini C, Bertini E, Carelli V, Comi GP, Donati MA, Federico
        A, Minetti C, Moggio M, Mongini T, Santorelli FM, Servidei S, Tonin P, Toscano
        A, Bruno C, Bello L, Caldarazzo Ienco E, Cardaioli E, Catteruccia M, Da Pozzo
        P, Filosto M, Lamperti C, Moroni I, Musumeci O, Pegoraro E, Ronchi D, Sauchelli
        D, Scarpelli M, Sciacco M, Valentino ML, Vercelli L, Zeviani M, Siciliano
        G. Redefining phenotypes associated with mitochondrial DNA single deletion.
        J Neurol. 2015;262:1301-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25808502</ArticleId></ArticleIdList></Reference><Reference><Citation>Manea
        EM, Leverger G, Bellmann F, Stanescu PA, Mircea A, L&#xe8;bre AS, R&#xf6;tig
        A, Munnich A. Pearson syndrome in the neonatal period: two case reports and
        review of the literature. J Pediatr Hematol Oncol. 2009;31:947-51.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">19881395</ArticleId></ArticleIdList></Reference><Reference><Citation>Melzer
        N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke
        B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Clinical features, pathogenesis,
        and treatment of myasthenia gravis: a supplement to the Guidelines of the
        German Neurological Society. J Neurol. 2016;263:1473-94.</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC4971048</ArticleId><ArticleId IdType="pubmed">26886206</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscatelli
        M, Ardissone A, Lamantea E, Zorzi G, Bruno C, Moroni I, Erbetta A, Chiapparini
        L. Kearns-Sayre syndrome: expanding spectrum of a "novel" mitochondrial leukomyeloencephalopathy.
        Neurol Sci. 2022;43:2081-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">35031921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mita
        S, Rizzuto R, Moraes CT, Shanske S, Arnaudo E, Fabrizi GM, Koga Y, DiMauro
        S, Schon EA. Recombination via flanking direct repeats is a major cause of
        large-scale deletions of human mitochondrial DNA. Nucleic Acids Res. 1990;18:561-7</Citation><ArticleIdList><ArticleId
        IdType="pmc">PMC333462</ArticleId><ArticleId IdType="pubmed">2308845</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel
        AS, Joris N, Meuli R, Jacquemont S, Ballhausen D, Bonaf&#xe9; L, Fattet S,
        Tolsa JF. Early neurological impairment and severe anemia in a newborn with
        Pearson syndrome. Eur J Pediatr. 2009;168:311-5.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">18553104</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh
        S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou
        J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J,
        Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S,
        Raboisson MJ, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner
        J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Cunningham
        ZZ, Rahman S, Chinnery PF. Patient care standards for primary mitochondrial
        disease: a consensus statement from the Mitochondrial Medicine Society. Genet
        Med. 2017;19:1380-97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804217</ArticleId><ArticleId
        IdType="pubmed">28749475</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitceathly
        RD, Rahman S, Hanna MG. Single deletions in mitochondrial DNA--molecular mechanisms
        and disease phenotypes in clinical practice. Neuromuscul Disord. 2012;22:577-86.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">22578526</ArticleId></ArticleIdList></Reference><Reference><Citation>Quijada-Fraile
        P, O''Callaghan M, Mart&#xed;n-Hern&#xe1;ndez E, Montero R, Garcia-Cazorla
        &#xc0;, de Arag&#xf3;n AM, Muchart J, M&#xe1;laga I, Pardo R, Garc&#xed;a-Gonzalez
        P, Jou C, Montoya J, Emperador S, Ruiz-Pesini E, Arenas J, Martin MA, Ormazabal
        A, Pineda M, Garc&#xed;a-Silva MT, Artuch R. Follow-up of folinic acid supplementation
        for patients with cerebral folate deficiency and Kearns-Sayre syndrome. Orphanet
        J Rare Dis. 2014;9:217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302586</ArticleId><ArticleId
        IdType="pubmed">25539952</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds
        E, Byrne M, Ganetzky R, Parikh S. Pediatric single large-scale mtDNA deletion
        syndromes: The power of patient reported outcomes. Mol Genet Metab. 2021;134:301-8.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">34862134</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer
        AM, McFarland R, Blakely EL, He L, Whittaker RG, Taylor RW, Chinnery PF, Turnbull
        DM. Prevalence of mitochondrial DNA disease in adults. Ann Neurol. 2008;63:35-9.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">17886296</ArticleId></ArticleIdList></Reference><Reference><Citation>Schon
        EA. Rearrangements of mitochondrial DNA. In: Holt I, ed. Genetics of Mitochondrial
        Diseases. Oxford, UK: Oxford University Press; 2003:111-24.</Citation></Reference><Reference><Citation>Trivedi
        M, Goldstein A, Arora G. Prophylactic pacemaker placement at first signs of
        conduction disease in Kearns-Sayre syndrome. Cardiol Young. 2018;28:1487-8.</Citation><ArticleIdList><ArticleId
        IdType="pubmed">30326976</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya
        VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C, Bradwin
        G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV. Urinary biomarkers for
        sensitive and specific detection of acute kidney injury in humans. Clin Transl
        Sci. 2008;1:200-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638059</ArticleId><ArticleId
        IdType="pubmed">19212447</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams
        TB, Daniels M, Puthenveetil G, Chang R, Wang RY, Abdenur JE. Pearson syndrome:
        unique endocrine manifestations including neonatal diabetes and adrenal insufficiency.
        Mol Genet Metab. 2012;106:104-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424738</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate
        PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate
        PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate
        PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId
        IdType="pubmed">20301382</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>'
    headers:
      Access-Control-Allow-Origin:
      - '*'
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Cache-Control:
      - private
      Connection:
      - Keep-Alive
      Content-Security-Policy:
      - upgrade-insecure-requests
      Content-Type:
      - text/xml; charset=UTF-8
      Date:
      - Thu, 05 Sep 2024 23:01:00 GMT
      Keep-Alive:
      - timeout=4, max=40
      NCBI-PHID:
      - D0BD9D8EE5AB4CE5000024EF8192ABF7.1.1.m_3
      NCBI-SID:
      - 9F2DC9796F45192B_45ABSID
      Referrer-Policy:
      - origin-when-cross-origin
      Server:
      - Finatra
      Set-Cookie:
      - ncbi_sid=9F2DC9796F45192B_45ABSID; domain=.nih.gov; path=/; expires=Fri, 05
        Sep 2025 23:01:00 GMT
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Transfer-Encoding:
      - chunked
      X-RateLimit-Limit:
      - '10'
      X-RateLimit-Remaining:
      - '5'
      X-UA-Compatible:
      - IE=Edge
      X-XSS-Protection:
      - 1; mode=block
      content-encoding:
      - gzip
    status:
      code: 200
      message: OK
version: 1
